Navin Jacob
Stock Analyst at UBS
(2.70)
# 1,897
Out of 5,237 analysts
29
Total ratings
64.29%
Success rate
18.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Navin Jacob
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Neutral | $181 → $190 | $202.78 | -6.30% | 15 | Feb 3, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $363 | $966.99 | -62.46% | 8 | Sep 22, 2022 | |
| RPRX Royalty Pharma | Upgrades: Buy | $51 | $51.65 | -1.26% | 1 | Nov 9, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $133.52 | - | 1 | Apr 27, 2020 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $92 | $111.28 | -17.33% | 4 | Apr 13, 2020 |
AbbVie
Feb 3, 2025
Maintains: Neutral
Price Target: $181 → $190
Current: $202.78
Upside: -6.30%
Eli Lilly and Company
Sep 22, 2022
Upgrades: Buy
Price Target: $363
Current: $966.99
Upside: -62.46%
Royalty Pharma
Nov 9, 2020
Upgrades: Buy
Price Target: $51
Current: $51.65
Upside: -1.26%
Gilead Sciences
Apr 27, 2020
Downgrades: Neutral
Price Target: n/a
Current: $133.52
Upside: -
Merck & Co.
Apr 13, 2020
Maintains: Buy
Price Target: $96 → $92
Current: $111.28
Upside: -17.33%